Our Pricing

Wegovy Online In Stock UK - All Doses Available Now

Published on: June 03, 2026

Finding wegovy online in stock uk can be challenging with widespread shortages across pharmacies. At Cured Pharmacy, we maintain stock across all Wegovy doses — from the 0.25mg starter pen through to the full 2.4mg maintenance dose — with transparent pricing from £79.00 and same-day prescription processing by UK-registered clinicians.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [1]. Semaglutide mimics the natural hormone GLP-1, which regulates appetite and food intake by acting on areas of the brain that control hunger.

In the landmark STEP 1 trial, participants using Wegovy alongside lifestyle modifications achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. This represents one of the most significant weight loss outcomes observed in clinical trials for pharmacological obesity treatment. The medication works by slowing gastric emptying, reducing appetite, and improving glycaemic control — effects that support sustainable weight management when combined with dietary changes and increased physical activity [2].

Wegovy Dosing Schedule and All Available Strengths

Wegovy follows a carefully designed dose escalation schedule to minimise gastrointestinal side effects whilst building therapeutic efficacy. The treatment begins with a 0.25mg weekly injection for the first month, then increases monthly through 0.5mg, 1mg, and 1.7mg doses before reaching the full maintenance dose of 2.4mg [3].

At Cured Pharmacy, we stock all five Wegovy pen strengths, ensuring continuity throughout your treatment journey without interruption. Each pre-filled pen delivers a single weekly dose, and our UK clinical team will prescribe the appropriate strength based on your current position in the escalation schedule. This graduated approach allows your body to adapt to the medication whilst reducing the likelihood of nausea, vomiting, and other common initial side effects.

What If I Miss a Dose?

If you miss your weekly Wegovy injection and fewer than five days have passed since your scheduled dose, take it as soon as you remember. If more than five days have elapsed, skip the missed dose and resume your normal schedule with the next injection [3]. Never double up doses to compensate for a missed injection, as this increases the risk of adverse gastrointestinal effects.

Wegovy Stock Availability Across UK Pharmacies

Since its UK launch, Wegovy has experienced significant supply constraints driven by unprecedented global demand and manufacturing capacity limitations. Novo Nordisk, the manufacturer, has implemented allocation systems across markets, and many traditional pharmacies report intermittent stock shortages particularly for starter doses and higher maintenance strengths.

As a specialist online pharmacy with established supply relationships, Cured Pharmacy maintains priority access to Wegovy stock across all dose strengths. Our procurement team works directly with licensed UK wholesalers to ensure consistent availability, and we update stock status in real-time on our platform. When you complete your clinical assessment with our prescribers, you can proceed with confidence knowing your prescribed dose is available for immediate dispensing and dispatch.

How We Maintain Consistent Stock

Our superintendent pharmacist Tarun Kumar oversees a dedicated supply chain management system that forecasts demand patterns and secures allocation commitments from multiple licensed wholesalers. This multi-source approach, combined with our focus on prescription weight management treatments, allows us to maintain stock resilience even during periods of national shortage.

Wegovy Online In Stock UK: Our Clinical Process

Every Wegovy prescription at Cured Pharmacy begins with a comprehensive online clinical assessment reviewed by UK-registered prescribers. The consultation takes under three minutes to complete and covers your medical history, current medications, weight management goals, and any contraindications that might affect suitability.

Our clinical team evaluates your assessment against NICE guidance and MHRA licensing criteria, which require a BMI of 30 kg/m² or above, or 27 kg/m² with associated weight-related health conditions such as type 2 diabetes, hypertension, or dyslipidaemia. If Wegovy is deemed appropriate and safe for your circumstances, a UK prescriber will issue your prescription electronically, and our pharmacy team dispenses your medication the same day for discreet next-day delivery. All treatment is subject to prescriber approval — we never auto-approve assessments or dispense without proper clinical oversight.

Common Side Effects and How to Manage Them

The most frequently reported side effects of Wegovy are gastrointestinal in nature, particularly during the dose escalation phase. In clinical trials, nausea occurred in approximately 44% of participants, diarrhoea in 30%, vomiting in 24%, and constipation in 24% [1]. These effects typically diminish as your body adapts to each dose level, which is why the graduated dosing schedule is essential.

To minimise gastrointestinal discomfort, eat smaller, more frequent meals rather than large portions, avoid high-fat and heavily processed foods, and stay well-hydrated throughout the day. If nausea persists beyond the first few weeks at a new dose, your prescriber may recommend remaining at your current strength for an additional month before escalating further. Serious side effects are rare but include pancreatitis, gallbladder problems, and hypoglycaemia in patients taking other glucose-lowering medications — contact your GP or NHS 111 immediately if you experience severe abdominal pain, persistent vomiting, or signs of low blood sugar [3].

When to Seek Medical Attention

Stop using Wegovy and seek immediate medical help if you develop symptoms of a serious allergic reaction (swelling of face, lips, tongue, or throat, difficulty breathing), signs of pancreatitis (severe upper abdominal pain radiating to your back, persistent vomiting), or symptoms of thyroid tumours (lump in the neck, hoarseness, difficulty swallowing). These events are uncommon but require urgent clinical evaluation.

Wegovy vs Other Weight Loss Treatments Available in the UK

Wegovy is one of several prescription weight management options licensed in the UK, each with distinct mechanisms, dosing schedules, and clinical efficacy profiles. Saxenda, which contains liraglutide (an earlier GLP-1 agonist), requires daily injections and demonstrated average weight loss of 8% in clinical trials — effective but less convenient than weekly options [4].

Mounjaro, containing tirzepatide, is the newest addition to the UK market and works as a dual GIP/GLP-1 receptor agonist. In head-to-head studies, tirzepatide produced greater weight reduction than semaglutide, with some participants achieving over 20% body weight loss [5]. However, Wegovy remains the most extensively studied option with the longest real-world safety data, and for many patients represents the optimal balance of efficacy, tolerability, and clinical experience. Your UK prescriber will discuss which treatment aligns best with your medical history, weight loss goals, and lifestyle preferences during your consultation.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
3. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Retrieved from https://www.medicines.org.uk/emc/product/13799/smpc [accessed 13 August 2026]
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine licensed for chronic weight management alongside a reduced-calorie diet and increased physical activity in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities.